Robert Keeley, MD
Pulmonary Disease · Roanoke, VANPI 1518903921
Payments from drug & device makers
Across 520 payments — averaging $21.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$2K
- Sanofi$888
- Mallinckrodt Hospital Products Inc.$770
- Mylan Specialty L.p.$606
- Genentech USA, Inc.$473
- plus $2K from 24 others
What the payments were for
- Food & beverage$10,86399%
- Education$1541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 120 | $3,631 |
| GSK | 149 | $2,292 |
| Sanofi | 37 | $888 |
| Mallinckrodt Hospital Products Inc. | 49 | $770 |
| Mylan Specialty L.p. | 33 | $606 |
| Genentech USA, Inc. | 23 | $473 |
| Boehringer Ingelheim | 15 | $314 |
| Novartis | 16 | $252 |
| Regeneron Healthcare Solutions, Inc. | 9 | $243 |
| AbbVie(2 entities) | 11 | $210 |
| Baxter Healthcare | 5 | $210 |
| Merck | 5 | $172 |
| Teva Pharmaceuticals USA, Inc. | 4 | $151 |
| Amgen(2 entities) | 5 | $125 |
| Mallinckrodt Enterprises LLC | 4 | $89 |
| CSL Behring | 4 | $80 |
| Inogen, Inc. | 3 | $66 |
| Philips North America LLC | 4 | $65 |
| ANI Pharmaceuticals, Inc. | 2 | $54 |
| Sunovion Pharmaceuticals Inc. | 5 | $50 |
| Electromed, Inc. | 4 | $42 |
| Pulmonx Corporation | 2 | $37 |
| Advanced Respiratory, Inc | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Verona Pharma, Inc. | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Optinose US, Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| United Therapeutics Corporation | 1 | $17 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,017 in reported general payments places this provider in the 70th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 246 | $172,633 |
| XolairOmalizumab | 12 | $99,195 |
| Dupixent PenDupilumab | 20 | $74,888 |
| Fasenra PenBenralizumab | 12 | $67,770 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 57 | $61,766 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $37,931 |
| Spiriva RespimatTiotropium Bromide | 50 | $34,396 |
| Atrovent HfaIpratropium Bromide | 42 | $20,757 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $13,712 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 293 | $11,460 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $8,941 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $8,619 |
| BreynaBudesonide/Formoterol Fumarate | 36 | $7,286 |
| Ventolin HfaAlbuterol Sulfate | 69 | $6,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $2,292 | $220,177331 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $3,631 | $75,47799 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $314 | $43,01662 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $151 | $2,948100 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Roanoke
- Moises CossioRoanoke$147K
- Frank BiscardiRoanoke$53K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.